• SVB Leerink Lowers BridgeBio Pharma Price Target to $24.00

    23 days ago - By ETF Daily News

    BridgeBio Pharma had its price objective lowered by stock analysts at SVB Leerink from $66.00 to $24.00 in a report issued on Monday, Briefing.com reports. The firm presently has an “outperform” rating on the stock. SVB Leerink's target price indicates a potential upside of 78.70% from the stock's current price.
    BBIO has been the subject of a number of other research reports. Zacks Investment Research raised shares of BridgeBio Pharma from a “sell” rating to a “hold” rating in a report on Wednesday, November 10th. HC Wainwright reissued a “buy” rating on shares of BridgeBio Pharma in a...
    Read more ...